CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
基于免疫球蛋白检测的大 B 细胞淋巴瘤治疗后循环肿瘤 DNA：真实世界结局
英文原题：Post-treatment circulating tumor DNA in large B-cell lymphoma with an immunoglobulin-based assay: real-world outcomes.
查看英文原题
Post-treatment circulating tumor DNA in large B-cell lymphoma with an immunoglobulin-based assay: real-world outcomes.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
使用循环肿瘤 DNA (ctDNA) 进行可测量残留病灶 (MRD) 分析是大 B 细胞淋巴瘤 (LBCL) 疗效评估的一种非侵入性方法，但需要支持其现实可行性和性能的数据。我们对 LBCL 患者进行了一项多中心回顾性研究，使用市售的免疫球蛋白重排靶向 ctDNA-MRD 检测 (clonoSEQM) 进行实时评估。我们的主要目标是评估免疫化疗或CAR-T 细胞 治疗后的治疗后 MRD。从样本采集到 MRD 结果的中位时间为 9 天。一线治疗后 (N=102)，12 个月无进展生存率 (PFS) 为 15%，可检测到不可检测 MRD 为 85%（HR 14.5，第 12 页）。
展开英文摘要原文
Measurable residual disease (MRD) analysis using circulating tumor DNA (ctDNA) is a non-invasive method of response assessment in large B-cell lymphoma (LBCL), but data supporting its real-world feasibility and performance are needed.
We conducted a multicenter, retrospective study of patients with LBCL assessed in real time with a commercially available, immunoglobulin rearrangement-targeted ctDNA-MRD assay (clonoSEQM).
Our primary objective was to assess post-treatment MRD after immunochemotherapy or chimeric antigen receptor T-cell (CAR-T) therapy. Median time from sample collection to MRD result was 9 days. Following frontline treatment (N=102), 12-month progression-free survival (PFS) was 15% versus 85% for detectable versus undetectable MRD (HR 14. 5, p.
论文信息
- 作者
- Gould P、Coskey D、Ma X、Wang S、Godbole S、Bond D、Ip A、Ananth S
- 第一作者单位
- Columbia University Irving Medical Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York.United States
- 通讯作者单位
- Columbia University Irving Medical Center, New York. hjc2157@cumc.columbia.edu.United States
- 期刊
- Haematologica2026 Aug 13
- 原文标识
- PubMed 42610418 · DOI 10.3324/haematol.2026.300901